NeuroVive Pharmaceutical AB (OTCMKTS:NEVPF)’s share price traded up 10.5% during trading on Tuesday . The company traded as high as $0.11 and last traded at $0.09, 2,450 shares changed hands during trading. A decline of 90% from the average session volume of 25,428 shares. The stock had previously closed at $0.08.
A number of equities research analysts recently commented on the company. ValuEngine raised NeuroVive Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. Zacks Investment Research cut NeuroVive Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, May 13th.
The firm has a 50-day moving average price of $0.11 and a two-hundred day moving average price of $0.12.
About NeuroVive Pharmaceutical (OTCMKTS:NEVPF)
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases.
Receive News & Ratings for NeuroVive Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroVive Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.